Birdwatch Note
2024-11-15 04:40:28 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
動画50秒のレムデシビルのエボラ試験で、副作用で54%が死亡し中止というのはファクトチェック済の誤情報です。 https://www.politifact.com/factchecks/2024/jun/27/instagram-posts/remdesivir-didnt-kill-covid-19-ebola-patients-as-s/ レムデシビルのエボラの臨床試験における死亡率54%が比較群より高かったのは事実ですが、対照群はプラセボではなく3種類の抗体療法を受けた３治療群です。レムデシビルが危険だった証拠はなく、対照群のエボラ患者の死亡率も全て34-50%で非常に高率です。 https://www.politifact.com/factchecks/2024/jun/27/instagram-posts/remdesivir-didnt-kill-covid-19-ebola-patients-as-s/ https://www.nejm.org/doi/full/10.1056/NEJMoa1910993 また、COVID-19の死亡に対するレムデシビルのランダム化比較試験の昨年のLancet系誌のメタアナリシスでは、レムデシビルは特定条件で患者の死亡率を減少させた事が報告されています。 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00528-8/fulltext
Written by 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1857253104733045163
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1857282496205066306
- noteId - 1857282496205066306
- participantId -
- noteAuthorParticipantId - 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE Participant Details
- createdAtMillis - 1731645628392
- tweetId - 1857253104733045163
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 動画50秒のレムデシビルのエボラ試験で、副作用で54%が死亡し中止というのはファクトチェック済の誤情報です。 https://www.politifact.com/factchecks/2024/jun/27/instagram-posts/remdesivir-didnt-kill-covid-19-ebola-patients-as-s/ レムデシビルのエボラの臨床試験における死亡率54%が比較群より高かったのは事実ですが、対照群はプラセボではなく3種類の抗体療法を受けた３治療群です。レムデシビルが危険だった証拠はなく、対照群のエボラ患者の死亡率も全て34-50%で非常に高率です。 https://www.politifact.com/factchecks/2024/jun/27/instagram-posts/remdesivir-didnt-kill-covid-19-ebola-patients-as-s/ https://www.nejm.org/doi/full/10.1056/NEJMoa1910993 また、COVID-19の死亡に対するレムデシビルのランダム化比較試験の昨年のLancet系誌のメタアナリシスでは、レムデシビルは特定条件で患者の死亡率を減少させた事が報告されています。 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00528-8/fulltext
Note Ratings
| rated at | rated by | |
| 2024-11-15 08:05:36 -0600 | Rating Details | |
| 2024-11-15 02:43:56 -0600 | Rating Details | |
| 2024-11-15 02:22:30 -0600 | Rating Details | |
| 2024-11-15 02:01:22 -0600 | Rating Details | |
| 2024-11-15 00:52:46 -0600 | Rating Details | |
| 2024-11-15 00:41:18 -0600 | Rating Details | |
| 2024-11-15 00:15:03 -0600 | Rating Details | |
| 2024-11-14 23:58:33 -0600 | Rating Details | |
| 2024-11-14 23:57:36 -0600 | Rating Details | |
| 2024-11-14 23:38:53 -0600 | Rating Details | |
| 2024-11-14 23:36:00 -0600 | Rating Details | |
| 2024-11-14 23:10:21 -0600 | Rating Details | |
| 2024-11-14 23:04:16 -0600 | Rating Details | |
| 2024-11-14 22:56:14 -0600 | Rating Details | |
| 2024-11-14 22:55:22 -0600 | Rating Details | |
| 2024-11-16 09:28:10 -0600 | Rating Details | |
| 2024-11-16 08:39:43 -0600 | Rating Details | |
| 2024-11-15 07:49:03 -0600 | Rating Details | |
| 2024-11-15 03:26:47 -0600 | Rating Details | |
| 2024-11-15 01:32:05 -0600 | Rating Details | |
| 2024-11-15 01:23:28 -0600 | Rating Details | |
| 2024-11-15 00:15:54 -0600 | Rating Details | |
| 2024-11-14 23:47:37 -0600 | Rating Details | |
| 2024-11-14 23:44:04 -0600 | Rating Details | |
| 2024-11-14 23:33:25 -0600 | Rating Details | |
| 2024-11-14 22:57:46 -0600 | Rating Details | |
| 2024-11-14 22:54:46 -0600 | Rating Details | |
| 2024-11-17 01:01:13 -0600 | Rating Details | |
| 2024-11-16 10:49:21 -0600 | Rating Details | |
| 2024-11-15 15:29:50 -0600 | Rating Details | |
| 2024-11-15 15:18:20 -0600 | Rating Details | |
| 2024-11-15 05:40:23 -0600 | Rating Details | |
| 2024-11-15 04:12:21 -0600 | Rating Details | |
| 2024-11-15 03:10:36 -0600 | Rating Details | |
| 2024-11-15 01:36:34 -0600 | Rating Details | |
| 2024-11-15 00:31:50 -0600 | Rating Details | |
| 2024-11-15 00:00:59 -0600 | Rating Details | |
| 2024-11-14 23:10:49 -0600 | Rating Details | |
| 2024-11-14 23:06:03 -0600 | Rating Details | |
| 2024-11-14 23:03:32 -0600 | Rating Details | |
| 2024-11-14 23:01:31 -0600 | Rating Details | |
| 2024-11-14 22:45:57 -0600 | Rating Details | |
| 2024-11-19 22:16:24 -0600 | Rating Details |